IPO - Klotho Neurosciences, Inc.
Form Type: S-3
Filing Date: 2025-07-07
Corporate Action: Ipo
Type: New
Accession Number: 000121390025061591
Filing Summary: Klotho Neurosciences, Inc. filed a registration statement under Form S-3 with the SEC on July 7, 2025, to offer securities worth up to $100,000,000, including common stock, preferred stock, warrants, and units. The filing indicates a provision for delayed or continuous offering and includes a detailed prospectus explaining the types of offerings, potential sale methods, and risks related to investment in the company's securities. The company focuses on gene therapy for neurodegenerative disorders, showcasing a commitment to developing innovative treatment solutions in partnership with leading scientific institutions. This includes in-licensed proprietary technologies and a forward-looking strategy to build a research and development pipeline for age-related diseases. An emphasis is placed on the importance of reading the entire prospectus, including risk factors and market conditions that may influence future offerings.
Additional details:
Approximate Date Of Commencement: From time to time after the effective date of this Registration Statement
Securities Offered: up to $100,000,000
Common Stock Symbol: KLTO
Warrants Symbol: KLTOW
Last Reported Sale Price: $1.06
Total Authorized Common Stock: 1,000,000,000 shares
Total Issued Common Stock: 52,703,070 shares
Total Issued Preferred Stock: 6,250,000 shares of Series B preferred stock
Form Type: CORRESP
Filing Date: 2025-02-07
Corporate Action: Ipo
Type: New
Accession Number: 000121390025011169
Filing Summary: Klotho Neurosciences, Inc. filed a request to accelerate the effective date of its Registration Statement on Form S-1, which was previously filed on January 30, 2025. The company seeks to have the Registration Statement declared effective at 4:30 p.m. ET on February 10, 2025, or as soon thereafter as practicable, unless a different time is requested by the company or its outside counsel, Paul Goodman. Any inquiries regarding this filing should be directed to Paul Goodman, Esq.
Additional details:
Registration Statement File Number: 333-284602
Effective Date Request Time: 4:30 p.m. ET
Contact Person Name: Paul Goodman
Contact Person Phone: 917-596-0905
Ceo Name: Joseph Sinkule
Form Type: S-1
Filing Date: 2025-01-30
Corporate Action: Ipo
Type: New
Accession Number: 000121390025008318
Filing Summary: On January 30, 2025, Klotho Neurosciences, Inc. filed a registration statement for an initial public offering (IPO) of shares. This S-1 filing includes prospective sales of up to 43,680,219 shares of common stock. Of this amount, 37,876,100 shares are intended for issuance to investors upon the conversion of promissory notes and exercise of warrants, while 5,804,119 shares are held by selling shareholders. The company has stated that it will not receive proceeds from the sale of shares by the selling stockholders, although it may obtain funds from the exercise of any warrants that are not exercised on a cashless basis. The offering price for the shares has been estimated based on market prices from January 27, 2025. The document emphasizes that the information is subject to change and the SEC has not approved the offerings. Investing in the shares presents significant risks and the company warns potential investors regarding the high degree of risk involved. The company is listed on the NASDAQ under the symbol 'KLTO.'
Additional details:
Approximate Date Of Commencement: As soon as practicable after this registration statement becomes effective
Common Stock Offered: 43,680,219
Common Stock Outstanding Prior To Offering: 27,080,915
Trading Symbol: KLTO
Dividend Policy: No cash dividends have been declared or paid, nor are expected in the foreseeable future.
Risk Factors: Investment involves significant risks including potential total loss of investment.
Comments
No comments yet. Be the first to comment!